FDA opens US to Lyrica generics
24-07-2019
CJEU backs Warner-Lambert in marketing authorisation dispute
18-02-2019
UK Supreme Court issues Warner-Lambert v Actavis ruling
14-11-2018
Pfizer expects $1.9bn loss due to patent expirations
31-07-2018
daneger / iStockphoto.com
The US Food and Drug Administration (FDA) has granted Pfizer paediatric exclusivity for Lyrica (pregabalin), extending the period of US market exclusivity for the drug by six months.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Pfizer, US Food and Drug Administration, Lyrica, pregabalin, patent extension, market exclusivity, paediatric exclusivity, patent expiry
